FDA asks Discovery Labs for more info on Surfaxin

Discovery Laboratories said Monday the Food and Drug Administration wants even more information for the company's new drug application on Surfaxin, designed to prevent respiratory distress in premature infants. This is the FDA's second request for more information from Discovery. If approved, Surfaxin would be Discovery's first product to reach market.

- read this story from the Philadelphia Business Journal for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.